Inflammation Treatment
Inflammation Treatment - Related Videos
01:38
Inflammation
0 Views •
2019
Overview In response to tissue injury and infection, mast cells initiate inflammation. Mast cells release chemicals that increase the permeability of adjacent blood capillaries and attract additional immune cells to the wound or site of infection. Neutrophils are phagocytic leukocytes that exit the bloodstream and engulf invading microbes. Blood clotting platelets seal the wound and fibers create a scaffold for wound healing. Macrophages engulf aging neutrophils to end the acute inflammatory...
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
07:50
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
0 Views •
Cited by 39 •
2012
Here we describe a novel high-content chemically induced inflammation assay aiming at the identification of immune-modulatory bioactives. We have successfully combined automated microscopy with custom developed software scripts enabling automated quantification of the inflammatory response as well as further data processing, analysis, mining, and storage.
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
0 Views •
Cited by 607 •
2012
Experimental models of inflammatory bowel disease have allowed us to examine the complex innate and adaptive immune responses associated with pathogenesis. Using histological scoring, quantification of pro-inflammatory cytokines and myeloperoxidase activity, one can begin to assess these responses seen in inflammatory bowel disease.
07:10
In vivo Imaging Method to Distinguish Acute and Chronic Inflammation
0 Views •
Cited by 25 •
2013
We describe a non-invasive imaging method for distinguishing inflammatory stages. Systemic delivery of luminol reveals areas of acute inflammation dependent upon MPO activity in neutrophils. In contrast, injection of lucigenin allows for visualization of chronic inflammation dependent upon Phox activity in macrophages.
FAQs
Effective treatment aims to moderate excessive inflammatory signaling and immune-cell recruitment rather than suppress every immune response. This distinction matters because inflammation can contribute to pain, swelling, and tissue injury, while some immune activity remains necessary for normal defense. Clinical decisions therefore balance symptom and tissue control against preservation of essential immune functions.
These options represent different levels of therapeutic targeting. Nonsteroidal anti-inflammatory drugs can address inflammatory symptoms, corticosteroids provide broader suppression of inflammatory activity, and targeted biologics focus on selected inflammatory pathways. The appropriate choice depends on the underlying disease, affected tissues, severity, and potential risks rather than on inflammation alone.
Reducing inflammation without addressing its source may provide incomplete control of the clinical problem. The same inflammatory features can occur in autoimmune disease, allergic reactions, or inflammatory injury, yet each setting may require a different strategy. Identifying the underlying condition helps clinicians match treatment intensity and mechanism to the biological process involved.
Clinicians weigh the location of inflammation, the tissues involved, disease severity, and the likelihood of treatment-related harm. Pain and swelling may improve when inflammatory activity is reduced, but overly broad suppression can compromise necessary immune defenses. This risk-benefit balance explains why therapy is individualized instead of applying one treatment to every inflammatory condition.
The clinical approach begins by considering the condition causing inflammation, the affected tissues, and the severity of the presentation. Clinicians then select among anti-inflammatory medicines, targeted biologics, or supportive measures according to the desired control of signaling, immune-cell recruitment, pain, and swelling. This structured matching supports more appropriate treatment decisions.
Supportive measures may be incorporated when clinicians need to limit pain, swelling, or other effects of inflammation while tailoring medication to the underlying condition. They can complement drugs such as nonsteroidal anti-inflammatory agents, corticosteroids, or biologics. Their role is especially relevant when treatment must control symptoms while avoiding unnecessary disruption of immune defenses.
Inflammation treatment is relevant across several clinical settings, including autoimmune disease, allergic reactions, and inflammatory injury. These conditions can differ in their causes, affected tissues, and severity, so the therapeutic approach is not interchangeable. Understanding the clinical context helps determine whether symptom-focused, broadly suppressive, targeted, or supportive strategies are most appropriate.
Current research aims to improve targeting so treatment can interrupt harmful inflammatory signaling more precisely while minimizing adverse effects. This direction is important because broad control may affect useful immune defenses, whereas more selective approaches may better distinguish damaging inflammation from necessary immune activity. Targeted treatment development therefore focuses on improving clinical benefit without increasing avoidable risk.